M1 Kliniken AG

  • WKN: A0STSQ
  • ISIN: DE000A0STSQ8
  • Land: Deutschland

Nachricht vom 04.10.2017 | 08:46

M1 Kliniken AG: M1 Kliniken AG decides to carry out a cash capital increase using the authorized capital with exclusion of subscription rights in the amount of up to 10% of the share capital to finance further growth investments.

M1 Kliniken AG / Key word(s): Capital Increase
M1 Kliniken AG: M1 Kliniken AG decides to carry out a cash capital increase using the authorized capital with exclusion of subscription rights in the amount of up to 10% of the share capital to finance further growth investments.

04-Oct-2017 / 08:46 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


M1 Kliniken AG decides to carry out a cash capital increase using the authorized capital with exclusion of subscription rights in the amount of up to 10% of the share capital to finance further growth investments.

Berlin, October 4, 2017 - The Management Board of M1 Kliniken AG (ISIN: DE000A0STSQ8, WKN: A0STSQ) today resolved to increase the company's share capital by up to 10% against cash contributions on the basis of the authorization granted by the Annual General Meeting on July 2,2015 with the approval of the Supervisory Board and partially utilizing the authorized capital 2015.

The share capital of the company is to be increased by the partial utilization of the authorized capital 2015 of currently EUR 15,000,000.00 by issuing up to 1,500,000 bearer shares to a total of up to EUR 16,500,000.00. The new shares are to be eligible for dividends as of January 1,2017 and are to be offered to institutional investors by means of a placement procedure in accordance with the exemption provisions for private placements without a prospectus and included in the existing listing of the company's shares. The placement price will not be significantly lower than the market price.

The final placement volume and the placement price will be determined by the Management Board, with the approval of the Supervisory Board, after the placement procedure has been completed and announced in a separate ad hoc announcement.

M1 Kliniken AG intends to use the proceeds from the capital increase to finance further growth investments and, in particular, to finance the opening of additional M1 Med-Beauty locations.

M1 Kliniken AG
The Board of Directors

Important information:

The information contained in this document is not intended for distribution or publication in the United States (including its territories and possessions), Australia, Canada or Japan or any other country where such publication may be illegal.

This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities.

In particular, this document does not constitute an offer to purchase securities in the United States of America. Securities may not be sold or sold in the United States of America without prior registration under the U. S. Securities may not be sold or sold in the United States of America without prior registration. Securities Act of 1933, as amended or without prior registration, are sold or offered for sale only on the basis of a derogation. The shares of M1 Kliniken AG are not and will not be sold in accordance with the regulations of the U. S. Securities Act of 1933, as amended, and will not be offered or sold in the United States of America.

In the member states of the European Economic Area that have implemented the Prospectus Directive, this document is addressed exclusively to "qualified investors" within the meaning of the Prospectus Directive 2003/71/EC (including all amendments, in particular to Directive 2010/73/EC) together with all relevant implementing measures in the relevant member states.

Language: German
Company: M1 Kliniken AG
Grünauer Str. 1
12557 Berlin
Germany
Phone: +49 (0)30-887086225
Fax: +49 (0)30-887086228
E-Mail: ir@m1-kliniken.de
Internet: www.m1-kliniken.de
ISIN: DE000A0STSQ8
WKN: A0STSQ
Stock exchanges: Frankfurt, Stuttgart, Düsseldorf, Xetra




Contact:
Patrick Brenske, Management Board
Corporate Communications
E-Mail: ir@m1-kliniken.de

04-Oct-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

Über 50% Kurschance bei Homes & Holiday AG, Börsengang läuft!

Der Ferienimmobilienspezialist geht zur Wachstumsbeschleunigung an die Börse. Die Zeichnungsfrist für die Homes & Holiday-Aktie (DE000A2GS5M9) läuft noch bis zum 21. Juni, Zeichnungen sind möglich per Kauforder am Börsenplatz München zu einem Preis von 2,50 €. Die Positionierung in Europas attraktivsten Ferienimmobilienregionen ist hervorragend. In Mallorca ist die Tochtergesellschaft Porta Mallorquina unter den TOP-3-Maklerhäusern, der Fokus des weiteren Wachstum liegt auf Standorten in Spanien und Deutschland. Dort befinden sich die Preise im starken Aufwärtstrend. Unser Research sieht den fairen Wert nach IPO bei 4,83 € je Aktie und damit eine hohe Kurschance.

News im Fokus

Daimler AG: Daimler passt Ergebnis-Erwartungen an

20. Juni 2018, 22:05

Aktuelle Research-Studie

artec technologies AG

Original-Research: artec technologies AG (von GBC AG): Kaufen

20. Juni 2018